Drugs / ASC11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05718518 | Jan → Apr 2023 | COVID-19 | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-12-07 | Ascletis Pharmaceuticals Co., Ltd. | Regulatory Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA ascletis.com ↗
Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19. |
| 2022-11-29 | Ascletis Pharmaceuticals Co., Ltd. | Regulatory Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA ascletis.com ↗ |
| 2022-11-23 | Ascletis Pharmaceuticals Co., Ltd. | Regulatory Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA ascletis.com ↗
U.S. FDA has approved to study safety, tolerability and pharmacokinetics of ASC11 at various doses in healthy subjects co-dosed with 100 mg ritonavir tablets. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-07 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA ascletis.com ↗ |
| 2022-11-29 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA ascletis.com ↗ |
| 2022-11-23 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA ascletis.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05718518 ↗ |